AIMS: Indirect comparison (IC) and direct comparison (DC) between aripiprazole and olanzapine for schizophrenia were conducted to compare their efficacy and safety. The objective was to determine the usability of IC and consistency of results delivered by the two comparisons. Factors that might influence the inconsistency of results were also investigated. METHODS: ICs and DCs were conducted using the change from baseline of the Positive and Negative Syndrome Scale (PANSS) total score as an efficacy endpoint and the dropout rate was selected as a safety endpoint. Placebo and risperidone were used as common comparators for ICs. RESULTS: A literature search identified 20 articles. The efficacy analysis gave results on the mean difference in PANSS change (95% CI) of -5.72 (-10.22, -1.22) in ICs using placebo as a common comparator and -7.41 (-15.96, 1.14) in DCs. When using risperidone as a common comparator, it was -9.15 (-20.12, 1.82). In rate ratio analysis of the all cause dropout rate, the IC result was 1.17 (0.83, 1.65) using placebo as a common comparator and 1.56 (0.57, 4.26) using risperidone as a common comparator. Both analyses gave consistent results between ICs and DCs. A slightly lower estimated value was observed in ICs using placebo. CONCLUSIONS: This study demonstrated that ICs between olanzapine and aripiprazole can deliver results consistent with those of DCs. It is also suggested that the selection of a common comparator is important when control group bias is suspected in the data set.
AIMS: Indirect comparison (IC) and direct comparison (DC) between aripiprazole and olanzapine for schizophrenia were conducted to compare their efficacy and safety. The objective was to determine the usability of IC and consistency of results delivered by the two comparisons. Factors that might influence the inconsistency of results were also investigated. METHODS: ICs and DCs were conducted using the change from baseline of the Positive and Negative Syndrome Scale (PANSS) total score as an efficacy endpoint and the dropout rate was selected as a safety endpoint. Placebo and risperidone were used as common comparators for ICs. RESULTS: A literature search identified 20 articles. The efficacy analysis gave results on the mean difference in PANSS change (95% CI) of -5.72 (-10.22, -1.22) in ICs using placebo as a common comparator and -7.41 (-15.96, 1.14) in DCs. When using risperidone as a common comparator, it was -9.15 (-20.12, 1.82). In rate ratio analysis of the all cause dropout rate, the IC result was 1.17 (0.83, 1.65) using placebo as a common comparator and 1.56 (0.57, 4.26) using risperidone as a common comparator. Both analyses gave consistent results between ICs and DCs. A slightly lower estimated value was observed in ICs using placebo. CONCLUSIONS: This study demonstrated that ICs between olanzapine and aripiprazole can deliver results consistent with those of DCs. It is also suggested that the selection of a common comparator is important when control group bias is suspected in the data set.
Authors: Andrew J Cutler; Ronald N Marcus; Sterling A Hardy; Amy O'Donnell; William H Carson; Robert D McQuade Journal: CNS Spectr Date: 2006-09 Impact factor: 3.790
Authors: W Wolfgang Fleischhacker; Robert D McQuade; Ronald N Marcus; Donald Archibald; René Swanink; William H Carson Journal: Biol Psychiatry Date: 2008-11-04 Impact factor: 13.382
Authors: Robert L Findling; Adelaide Robb; Margaretta Nyilas; Robert A Forbes; Na Jin; Svetlana Ivanova; Ronald Marcus; Robert D McQuade; Taro Iwamoto; William H Carson Journal: Am J Psychiatry Date: 2008-09-02 Impact factor: 18.112
Authors: John M Kane; Olawale Osuntokun; Ludmila A Kryzhanovskaya; Wen Xu; Virginia L Stauffer; Susan B Watson; Alan Breier Journal: J Clin Psychiatry Date: 2009-03-24 Impact factor: 4.384
Authors: Joseph P McEvoy; Jeffrey A Lieberman; Diana O Perkins; Robert M Hamer; Hongbin Gu; Arthur Lazarus; Dennis Sweitzer; Christina Olexy; Peter Weiden; Stephen D Strakowski Journal: Am J Psychiatry Date: 2007-07 Impact factor: 18.112
Authors: Stephen R Marder; Michelle Kramer; Lisa Ford; Els Eerdekens; Pilar Lim; Mariëlle Eerdekens; Adam Lowy Journal: Biol Psychiatry Date: 2007-06-28 Impact factor: 13.382